Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Sees Large Growth in Short Interest

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) saw a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 10,430,000 shares, a growth of 28.9% from the March 31st total of 8,090,000 shares. Approximately 2.2% of the company’s stock are short sold. Based on an average daily volume of 4,090,000 shares, the short-interest ratio is currently 2.6 days.

Insider Activity

In related news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the company’s stock in a transaction on Wednesday, March 6th. The shares were purchased at an average price of 0.95 per share, for a total transaction of 57,409,487.05. Following the purchase, the insider now owns 116,773,394 shares in the company, valued at 110,934,724.30. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 5.72% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Perspective Therapeutics

Large investors have recently bought and sold shares of the business. ZWJ Investment Counsel Inc. bought a new stake in Perspective Therapeutics during the first quarter worth approximately $26,000. Simplicity Wealth LLC acquired a new stake in shares of Perspective Therapeutics in the first quarter worth $40,000. Taylor & Morgan Wealth Management LLC boosted its holdings in shares of Perspective Therapeutics by 8.7% during the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock worth $251,000 after buying an additional 50,000 shares during the period. HighTower Advisors LLC acquired a new position in Perspective Therapeutics in the 3rd quarter valued at $314,000. Finally, Perkins Capital Management Inc. bought a new position in Perspective Therapeutics in the 3rd quarter worth $731,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Price Performance

CATX stock opened at 1.58 on Friday. The company has a market capitalization of $927.33 million, a price-to-earnings ratio of -15.80 and a beta of 1.56. The company has a quick ratio of 1.07, a current ratio of 1.07 and a debt-to-equity ratio of 0.02. Perspective Therapeutics has a 12 month low of 0.21 and a 12 month high of 1.77.

Analyst Upgrades and Downgrades

CATX has been the subject of several recent research reports. B. Riley increased their price objective on Perspective Therapeutics from $1.20 to $1.70 and gave the stock a “buy” rating in a report on Tuesday, April 9th. Oppenheimer reaffirmed an “outperform” rating and set a $1.50 price target (up from $1.20) on shares of Perspective Therapeutics in a research note on Monday, April 1st.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.